Page contents Key factsDecisionRelated medicine informationKey facts Invented name Nerlynx Active Substance neratinib Therapeutic area Oncology Decision number P/0246/2020 PIP number EMEA-002783-PIP01-20 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of breast cancer Route(s) of administration Oral use Contact for public enquiries Pierre Fabre MédicamentE-mail: medical_information@pierre-fabre.comTel. +33 800326326 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 15/07/2020DecisionP/0246/2020: EMA decision of 15 July 2020 on the granting of a product specific waiver for neratinib (Nerlynx), (EMEA-002783-PIP01-20)AdoptedReference Number: EMA/316758/2020 English (EN) (226.51 KB - PDF)First published: 16/06/2021ViewRelated medicine informationNerlynxShare this page